PARP1 and malignant colon neoplasm: The 40% fractions maintained the antiproliferative activity previously observed in the crude homogenates, and exhibited synergistic antiproliferative effects with the CRC chemotherapeutic drugs 5FU and OXA; induction of caspase 8 and 9 overexpression, and PARP1; cytotoxic effects on colon cancer cell tumorspheres; and antiangiogenic activity.